Inflarx N.V. (NASDAQ:IFRX) Has Increase in Shorts

The stock of Inflarx N.V. (NASDAQ:IFRX) registered an increase of 31.95% in short interest. IFRX’s total short interest was 1.24M shares in September as published by FINRA. Its up 31.95% from 941,700 shares, reported previously. With 1.56M shares average volume, it will take short sellers 1 days to cover their IFRX’s short positions. The short interest to Inflarx N.V.’s float is 8.17%.

The stock decreased 0.66% or $0.02 during the last trading session, reaching $3. About 241,187 shares traded. InflaRx N.V. (NASDAQ:IFRX) has declined 90.11% since September 13, 2018 and is downtrending. It has underperformed by 90.11% the S&P500.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $78.92 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa – Nasdaq” on June 05, 2019, also Seekingalpha.com with their article: “InflaRx Tanks 91.79% As IFX-1 Phase II Trial Flops, Provides Bargain Buy For Competitor ChemoCentryx – Seeking Alpha” published on June 08, 2019, Finance.Yahoo.com published: “Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX) – Yahoo Finance” on June 29, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx Reports Second Quarter 2019 Financial & Operating Results – GlobeNewswire” published on August 14, 2019 as well as Globenewswire.com‘s news article titled: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” with publication date: February 14, 2019.

InflaRx N.V. (NASDAQ:IFRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.